BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.

(BHVN)
  Report
Real-time Estimate Cboe BZX  -  11:13 2022-08-12 am EDT
147.56 USD   -0.03%
08/08Pfizer Strikes $5.4 Billion Buyout Deal For Global Blood Therapeutics, Eyeing Sickle Cell Disease Portfolio
MT
08/08Biohaven reports second quarter 2022 financial results and reports recent business developments
AQ
08/08Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln deal
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sector Update: Health Care Stocks Still Edging Higher This Afternoon

05/10/2022 | 01:52pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. -0.01% 147.59 Delayed Quote.7.11%
EVAXION BIOTECH A/S 2.14% 2.86 Delayed Quote.-36.65%
INTRA-CELLULAR THERAPIES, INC. -3.68% 54.945 Delayed Quote.8.94%
MERCK & CO., INC. 0.73% 89.55 Delayed Quote.16.04%
NASDAQ COMPOSITE 1.05% 12915.33 Real-time Quote.-17.83%
PFIZER, INC. 2.12% 49.3275 Delayed Quote.-18.22%
All news about BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
08/08Pfizer Strikes $5.4 Billion Buyout Deal For Global Blood Therapeutics, Eyeing Sickle Ce..
MT
08/08Biohaven reports second quarter 2022 financial results and reports recent business deve..
AQ
08/08Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln deal
RE
08/08Wedbush Downgrades Biohaven Pharmaceutical to Neutral From Outperform, Noting Pfizer De..
MT
08/05BIOHAVEN PHARMACEUTICAL : REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND REPORTS RECENT..
PU
08/05BIOHAVEN PHARMACEUTICAL HOLDING CO LTD. Management's Discussion and Analysis of Financ..
AQ
08/05Biohaven Pharmaceutical Holding Company Reports Bigger Q2 Loss Despite Higher Revenue
MT
08/05Earnings Flash (BHVN) BIOHAVEN PHARMACEUTICAL HOLDING COMPANY Posts Q2 Revenue $215.1M
MT
08/05Earnings Flash (BHVN) BIOHAVEN PHARMACEUTICAL HOLDING COMPANY Posts Q2 Loss $-3.82
MT
08/05Biohaven Pharmaceutical Holding Company Ltd. Reports Earnings Results for the Second Qu..
CI
More news
Analyst Recommendations on BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
More recommendations
Financials (USD)
Sales 2022 1 078 M - -
Net income 2022 -960 M - -
Net Debt 2022 212 M - -
P/E ratio 2022 -10,4x
Yield 2022 -
Capitalization 10 553 M 10 553 M -
EV / Sales 2022 9,99x
EV / Sales 2023 8,40x
Nbr of Employees 928
Free-Float 87,0%
Chart BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Duration : Period :
Biohaven Pharmaceutical Holding Company Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 147,61 $
Average target price 153,56 $
Spread / Average Target 4,03%
EPS Revisions
Managers and Directors
Vladimir Coric Chairman & Chief Executive Officer
Matthew Buten Chief Financial Officer
Charles Conway Chief Scientific Officer
Elyse Stock Chief Medical Officer
Melissa Beiner Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.7.11%10 553
MODERNA, INC.-32.35%67 212
LONZA GROUP AG-23.32%46 073
IQVIA HOLDINGS INC.-14.23%45 135
SEAGEN INC.12.57%32 099
ALNYLAM PHARMACEUTICALS, INC.35.27%27 533